

Dakai Liu and Elazar Rabbani

Serial No. 09/046,840

Filed: March 24, 1998

Page 3 [Amendment Under 37 C.F.R. §1.11 (In Response To The December 3, 2002 Office Action) -- July 16, 2003]

KINDLY AMEND THIS APPLICATION AS FOLLOWS:

In the Claims:

Claims 68-84 (canceled)

85. (NEW) A first vector comprising:

- i) retroviral sequences;
- ii) retroviral packaging component or components;
- iii) non-retroviral viral vector sequences; and
- iv) nucleic acid sequences coding for an exogenous gene or exogenous nucleic acid sequence;

RECEIVED

JUL 18 2003

OFFICE OF PETITIONS

wherein when introduced into a packaging cell said first vector produces a second viral vector comprising:

- (a) said non-retroviral viral vector sequences; and
- (b) said exogenous gene or exogenous nucleic acid sequences, and

wherein said packaging cell provides one or more packaging components for said second viral vector.

86. (NEW) The first vector of claim 85, wherein said retroviral sequences (i) comprise one or more Long Terminal Repeat (LTR) sequences.

87. (NEW) The first vector of claim 85, wherein said retroviral packaging component or components (ii) comprise retroviral proteins.

88. (NEW) The first vector of claim 87, wherein said retroviral proteins are part of a surface or envelope of said first vector.

① 89. (NEW) The first vector of claim 85, wherein said retroviral packaging component or components (ii) comprise at least two different retroviral proteins.

90. (NEW) The first vector of claim 85, wherein said non-retroviral viral vector sequences (iii) comprise adeno-associated virus (AAV) sequences.

91. (NEW) The first vector of claim 85, wherein said adeno-associated virus (AAV) sequences comprise Inverted Terminal Repeat (ITR) sequences.

92. (NEW) The first vector of claim 85, wherein said second viral vector further comprises one or more promoters, or one or more enhancer regions, or an integration segment or a terminator.

93. (NEW) The first vector of claim 85, wherein said second viral vector further comprises a combination of any or all of one or more promoters, one or more enhancer regions, an integration segment or a terminator.

94. (NEW) The first vector of claim 85, wherein said exogenous gene or exogenous nucleic acid sequences code for a protein or an antisense sequence.

95. (NEW) A packaging cell of claim 85, wherein said packaging cell comprises a receptor for said first vector.

96. (NEW) A packaging cell of claim 85, wherein said packaging cell lacks a receptor for said first vector.

97. (NEW) A packaging cell of claim 85, wherein said packaging cell comprises a receptor for said second vector.

98. (NEW) A packaging cell of claim 85, wherein said packaging cell lacks a receptor for said second vector.

99. (NEW) A packaging cell of claim 85, wherein said packaging cell comprises a receptor for said first vector and a receptor for said second vector.

100. (NEW) A packaging cell of claim 85, wherein said packaging cell lacks a receptor for said first vector and lacks a receptor for said second vector.

101. (NEW) The packaging cell of claim 85, wherein said packaging cell is derived from NIH 3T3, U937, H9 or 293 cell lines.

102. (NEW) The packaging cell of claim 85, wherein said packaging components for said second viral vector are derived from sequences stably integrated into a chromosome or chromosomes of said packaging cell.

103. (NEW) The packaging cell of claim 85, wherein said packaging components for said second viral vector are derived from transient expression of non-integrated nucleic acid sequences.

104. (NEW) A cell line comprising:

- i) retroviral sequences;
- ii) non-retroviral viral vector sequences;
- iii) nucleic acid sequences coding for an exogenous gene or exogenous nucleic acid sequence; and
- iv) packaging component or components for said non-retroviral viral vector sequences.

105. (NEW) The cell line of claim 104, wherein said retroviral sequences i) comprise all or a part of a retroviral LTR sequence.

106. (NEW) The cell line of claim 104, wherein said non-retroviral viral vector sequences ii) comprise AAV sequences.

107. (NEW) The cell line of claim 106, wherein said AAV sequences comprise ITR sequences.

108. (NEW) The cell line of claim 104, wherein said second viral vector further comprises one or more promoters, or one or more enhancer regions, or an integration segment or a terminator.

109. (NEW) The cell line of claim 104, wherein said second viral vector further comprises a combination of any or all of one or more promoters, one or more enhancer regions, an integration segment or a terminator.

Dakai Liu and Elazar Rabbani

Serial No. 09/046,840

Filed: March 24, 1998

Page 7 [Amendment Under 37 C.F.R. §1.11 (In Response To The December 3,
2002 Office Action) -- July 16, 2003]

110. (NEW) The cell line of claim 109, wherein said exogenous gene or
exogenous nucleic acid sequences code for a protein or an antisense sequence.

* * * * *